Mutations in the omicron variant of the SARS-CoV-2 virus may impact certain molecular tests for COVID-19, the Food and Drug Administration announced yesterday. Specifically, FDA expects a Tide Laboratories test to produce false negative results for the omicron variant and is working with the manufacturer to address the issue. The agency said it does not believe the test is used for high-volume testing, and lists laboratories that perform the test. FDA also identifies certain tests that are less sensitive to a mutation in the omicron variant, but said it does not expect the variant to impact the overall sensitivity of those tests. The update includes recommendations for clinical laboratory staff and health care providers using these tests. 

Related News Articles

Headline
During the COVID-19 public health emergency, the Centers for Medicare & Medicaid Services will continue to exercise enforcement discretion under the…
Headline
The Centers for Disease Control and Prevention Friday updated its COVID-19 infection control guidance for U.S. health care settings based on current…
Headline
The Food and Drug Administration yesterday advised people who get a negative result from an at-home COVID-19 antigen test to test themselves again after…
Headline
The Centers for Disease Control and Prevention today released updated guidance to help people protect themselves and others if they are exposed to, sick or…
Headline
The Food and Drug Administration today granted full approval of Pfizer’s COVID-19 vaccine for young teens, covering the age group spanning 12 to 15 years old.…
Headline
The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment…